Effects of in vitro glycation on Fe3+ binding and Fe 3+ isoforms of transferrin

Clinical Chemistry

Volumn 50, Issue 9, 2004, Pages 1640-1649

  Van Campenhout, Ann ^a   Van Campenhout, Christel ^b   Lagrou, Albert René ^a   Manuel Y Keenoy, Begoña ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC ION; FERROUS CHLORIDE; GLUCOSE; ISOPROTEIN; NITRILOTRIACETATE IRON; TRANSFERRIN;

AMINO TERMINAL SEQUENCE; ANTIOXIDANT ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; GLYCATION; HUMAN; IRON BINDING CAPACITY; ISOELECTRIC FOCUSING; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; SPECTROPHOTOMETRY; STEADY STATE;

FERRIC COMPOUNDS; FRUCTOSAMINE; GLUCOSE; GLYCOSYLATION; HUMANS; ISOELECTRIC FOCUSING; PROTEIN ISOFORMS; TRANSFERRIN;

EID: 4344640572     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.033811     Document Type: Article

References (53)

1. de Jong G, van Dijk JP, van Eijk HG. The biology of transferrin. Clin Chim Acta 1990;190:1-46.
2. van Eijk HG, van Noort WL, Kroos MJ, van der Heul C. Analysis of the iron-binding sites of transferrin by isoelectric focussing. J Clin Chem Clin Biochem 1978;16:557-60.
3. van Noort WL, de Jong G, van Eijk HG. Purification of isotransferrins by concanavalin A Sepharose chromatography and preparative isoelectric focusing. Eur J Clin Chem Clin Biochem 1994;32:885-92.
4. van Eijk HG, van Noort WL. The analysis of human serum transferrins with the Phastsystem: quantitation of microheterogeneity. Electrophoresis 1992;13:354-8.
5. Gutteridge JM, Rowley DA, Halliwell B. Superoxide-dependent formation of hydroxyl radical and lipid peroxidation in the presence of iron salts. Detection of 'catalytic' iron and anti-oxidant activity in extracellular fluids. Biochem J 1982;206:605-9.
6. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001;44:129-46.
7. Baynes JW. Role of oxidative stress in the development of complications in diabetes. Diabetes 1991;40:405-12.
8. Wolff SP. Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull 1993;49:642-52.
9. Cutler P. Deferoxamine therapy in high-ferritin diabetes. Diabetes 1989;38:1207-10.
10. Tuomainen TP, Nyyssönen K, Salonen R, Tervahauta A, Korpela H, Lakka T, et al. Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1,013 eastern Finnish men. Diabetes Care 1997;20:426-8.
11. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002;51:2348-54.
12. Van Campenhout A, Van Campenhout CM, Lagrou AR, Manuel-y-Keenoy B. Transferrin modifications and lipid peroxidation: implications in diabetes mellitus. Free Radic Res 2003;37:1069-77.
13. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
14. Breuer W, Cabantchik ZI. A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal Biochem 2001;299:194-202.
15. Gambino R, Desvarieux E, Orth M, Matan H, Ackattupathil T, Lijoi E, et al. The relation between chemically measured total iron-binding capacity concentrations and immunologically measured transferrin concentrations in human serum. Clin Chem 1997;43:2408-12.
16. van Noort WL, van Eijk HG. Separation of human serum and cerebrospinal fluid transferrins in subfractions by isoelectric focusing with Phastsystem™ and quantitationswith the Ultroscan™ XL densitometer. Sci Tools 1992;36:1-6.
17. de Jong G, van Eijk HG. Microheterogeneity of human serum transferrin: a biological phenomenon studied by isoelectric focusing in immobilized pH gradients. Electrophoresis 1988;9:589-98.
18. Potter BJ, Chapman RWG, Nunes RM, Sorrentino D, Scherlock S. Transferrin metabolism in alcoholic liver disease. Hepatology 1985;5:714-21.
19. Jaeken J, Carchon H. The carbohydrate-deficient glycoprotein syndromes: an overview. J Inherit Metab Dis 1993;16:813-20.
20. Stibler H. Carbohydrate-deficient transferrin in serum: a new marker of potentially harmful alcohol consumption reviewed. Clin Chem 1991;37:2029-37.
21. Whitfield JB, Fletcher LM, Murphy TL, Powell LW, Halliday J, Heath AC, et al. Smoking, obesity, and hypertension alter the dose-response curve and test sensitivity of carbohydrate-deficient transferrin as a marker of alcohol intake. Clin Chem 1998;44:2480-9.
22. Zak O, Aisen P. Nonrandom distribution of iron in circulating human transferrin. Blood 1986;68:157-61.
23. Rauch SD. Transferrin microheterogeneity in human perilymph. The Laryngoscope 2000;110:545-52.
24. Hackler R, Arndt T, Tilmann KO, Gressner AM. Effect of separation conditions on automated isoelectric focusing of carbohydrate-deficient transferrin and other human isotransferrins using the PhastSystem. Anal Biochem 1995;230:281-9.
25. Aasa R, Malmstroem BG, Saltman P. The specific binding of iron(III) and copper(II) to transferrin and conalbumin. Biochim Biophys Acta 1963;75:203-22.
26. Harris WR, Pecoraro VL. Thermodyncimic binding constants for gallium transferrin. Biochemistry 1983;22:292-9.
27. Harris WR. Thermodynamic binding constants of the zinc-human serum transferrin complex. Biochemistry 1983;22:3920-6.
28. 3+. Clin Chem 1987;33:405-7.
29. Baldwin DA, De Sousa DM, Von Wandruszka RM. The effect of pH on the kinetics of iron release from human transferrin. Biochim Biophys Acta 1982;719:140-6.
30. Congiu-Castellano A, Barteri M, Castagnola M, Bianconi A, Borghi E, Della Longa S. Structure-function relationship in the serotransferrin: the role of the pH on the conformational change and the metal ions release. Biochem Biophys Res Commun 1994;198:646-52.
31. Messori L, Poggetto GD, Monnanni R, Hirose J. The pH dependent properties of metallotransferrins: a comparative study. Biometals 1997;10:303-13.
32. 3+ by transferrin. Implications for the interlocking sites hypothesis. J Biol Chem 1975;250:2182-8.
33. Zak O, Ikuta K, Aisen P. The synergistic anion-binding sites of human transferrin: chemical and physiological effects of site-directed mutagenesis. Biochemistry 2002;41:7416-23.
34. Bates GW, Schlabach MR. The reaction of ferric salts with transferrin. J Biol Chem 1973;248:3228-32.
35. Bates GW, Wernicke J. The kinetics and mechanism of iron(III) exchange between chelates and transferrin. IV. The reaction of transferrin with iron(III) nitrilotriacetate. J Biol Chem 1971;246:3679-85.
36. Bates GW, Billups C, Saltman P. The kinetics and mechanism of iron(III) exchange between chelates and transferrin. I. The complexes of citrate and nitrilotriacetic acid. J Biol Chem 1967;242:2810-5.
37. Bali PK, Aisen P. Receptor-modulated iron release from transferrin: differential effects on N- and C-terminal sites. Biochemistry 1991;30:9947-52.
38. Mason AB, He QY, Halbrooks PJ, Evers SJ, Gumerov DR, Kaltashov IA, et al. Differential effect of a His tag at the N- and C-termini: functional studies with recombinant human serum transferrin. Biochemistry 2002;41:9448-54.
39. Aisen P, Leibman A, Zweier J. Stoichiometric and site characteristics of the binding of iron to human transferrin. J Biol Chem 1978;253:1930-7.
40. Thompson CP, Grady JK, Chasteen ND. The influence of uncoordinated histidines on iron release from transferrin. A chemical modification study. J Biol Chem 1986;261:13128-34.
41. Zak O, Trinder D, Aisen P. Primary receptor-recognition site of human transferrin is in the C-terminal lobe. J Biol Chem 1994;269:7110-4.
42. Huebers HA, Josephson B, Huebers E, Csiba E, Finch CA. Occupancy of the iron binding sites of human transferrin. Proc Natl Acad Sci U S A 1984;81:4326-30.
43. DiRusso SC, Check IJ, Hunter RL. Quantification of apo-, mono-, and diferric transferrin by polyacrylamide gradient gel electrophoresis in patients with disorders of iron metabolism. Blood 1985;66:1445-51.
44. Beguin Y, Huebers HA, Finch CA. Random distribution of iron among the two binding sites of transferrin in patients with various hematologic disorders. Clin Chim Acta 1988;173:299-304.
45. Leibman A, Aisen P. Distribution of iron between the binding sites of transferrin in serum: methods and results in normal human subjects. Blood 1979;53:1058-65.
46. Williams J, Moreton K. The distribution of iron between the metal-binding sites of transferrin human serum. Biochem J 1980;185:483-8.
47. Surgenor DM, Koechlin BA, Strong LE. Chemical, clinical and immunological studies on the products of human plasma fractionation. XXXVII. The metal-combining globulin of human plasma. J Clin Invest 1949;28:73.
48. Qian M, Liu M, Eaton JW. Transition metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Commun 1998;250:385-9.
49. Fujimoto S, Kawakami N, Ohara A. Nonenzymatic glycation of transferrin: decrease of iron-binding capacity and increase of oxygen radical production. Biol Pharm Bull 1995;18:396-400.
50. Gutteridge JM, Quintan GJ. Antioxidant protection against organic and inorganic oxygen radicals by normal human plasma: the important primary role for iron-binding and iron-oxidising proteins. Biochim Biophys Acta 1992;1159:248-54.
51. Hirose M. The structural mechanism for iron uptake and release by transferrins. Biosci Biotechnol Biochem 2000;64:1328-36.
52. Austin GE, Mullins RH, Morin LG. Non-enzymic glycation of individual plasma proteins in normoglycemic and hyperglycemic patients. Clin Chem 1987;33;2220-4.
53. Mauricio D, Pérez A, Riera A, Arroyo JA, de Leiva A, Gimferrer E. Serum parameters of iron metabolism in type I (insulin dependent) diabetes mellitus. Diabetes Nutr Metab 1995;8:315-6.